Aprea logo 445pt.png
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
November 06, 2019 09:15 ET | Aprea Therapeutics
BOSTON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova New Letterhead Logo (002).JPG
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
October 24, 2019 07:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
September 23, 2019 08:52 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova New Letterhead Logo (002).JPG
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
September 16, 2019 07:30 ET | Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...